Anti-IgE therapy: clinical utility beyond asthma.
Thomas B
TB
Casale
Jeffrey
J
Stokes
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D003888:Desensitization, Immunologic; D005512:Food Hypersensitivity / Q000188:drug therapy; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D000069444:Omalizumab; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D014581:Urticaria / Q000188:drug therapy
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C026408:anti-IgE antibodies; D000069444:Omalizumab; C472419:talizumab